A Phase 3 interventional study of Faster-acting insulin aspart and insulin aspart in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 155 sites in 18 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2019-06-05.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.
Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one is the 2nd largest by enrollment, is one of 5 that started in 2016, is one of 24 in phase 3, and was the 61st registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 7–18
Defymed · Sites in France
Ages 18+
By country, each count listing its studies:
Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 1 Year to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 3 · Phase 3 26 · Phase 4 24
First in 1989; this study’s year is marked. 5 started in 2016.
This study's enrollment of 834 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 50 across the 87 interventional studies. Of the 81 that completed or were terminated, 21 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 87 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 7th largest by enrollment of the 149 interventional ones that give a count, is one of 4 that started in 2016, is one of 54 in phase 3, and was the 190th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
2 of the studies testing Insulin Aspart in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05221359DefymedPilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes | 2026-12 |
| NCT06532461Steno Diabetes Center CopenhagenA Trial of Three- and Seven-days Insulin Infusions Set | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1 diabetes.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 834 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: - Male or female, 1 year above or equal to age below 18 years at the time of signing and below 18 years at the time of randomisation - Diagnosed with type 1 diabetes mellitus (based on clinical judgement and supported by laboratory analysis as per local guidelines) - Ongoing daily treatment with a basal-bolus insulin regimen using basal insulin analogue or Neutral Protamine Hagedorn (NPH) insulin for at least 90 days prior to the screening visit - (glycosylated ) below or equal 9.5% (80 mmol/mol) analysed by the central laboratory at the screening visit Exclusion Criteria: - More than one episode of diabetic ketoacidosis requiring hospitalisation within the last 90 days prior to the screening visit - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Faster-acting insulin aspart · Drug: insulin degludec
Drug: insulin aspart · Drug: insulin degludec
Drug: Faster-acting insulin aspart · Drug: insulin degludec
For subcutaneous (s.c., under the skin) injection once daily.
For subcutaneous (s.c., under the skin) injection once daily.
For subcutaneous (s.c., under the skin) injection once daily.
Change in the Percentage of HbA1c
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related participant-site contact and included data collected after a subject discontinued trial product.
Time frame: Week 0, Week 26
Change in 8-point SMPG Profile: Mean PPG Over All Three Meals
Change from baseline (week 0) in mean post prandial glucose (PPG) over all three meals was evaluated after 26 weeks of randomisation. PPG for each meal (breakfast, lunch and main evening meal) was recorded by the participant as part of the 8-point self-measured plasma glucose (SMPG) profile. Mean PPG over all three meals was derived as the mean of all corresponding mean meal. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in 8-point SMPG Profile: PPG Increment Over All Three Meals
Change from baseline (week 0) in mean PPG increment over all three meals was evaluated after 26 weeks of randomisation. Postprandial glucose (PPG) increment for each meal (breakfast, lunch and main evening meal) was derived from the 8-point profile as the difference between PPG (1 hour after the meal) values and the plasma glucose (PG) value before meal. The mean of the derived increments was then calculated separately for each meal. Mean PPG increment over all three meals was derived as the mean of all corresponding mean meal increments. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in 8-point SMPG Profile: Individual Meal (Breakfast, Lunch and Main Evening Meal) PPG
Change from baseline (week 0) in individual meal (breakfast, lunch and main evening meal) PPG was evaluated after 26 weeks of randomisation. PPG for each meal was recorded by the participant as part of the 8-point SMPG profile. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in 8-point SMPG Profile: Individual Meal (Breakfast, Lunch and Main Evening Meal) PPG Increment
Change from baseline (week 0) in individual meal (breakfast, lunch and main evening meal) PPG increment was evaluated after 26 weeks of randomisation. PPG increment for each meal was derived from the 8-point profile as the difference between PPG values (1 hour after the meal) and the PG value before meal. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in 8-point SMPG Profile: Mean of the 8-point Profile
Change from baseline (week 0) in mean of the 8-point SMPG profile was evaluated after 26 weeks of randomisation. SMPG values were recorded at 8 time-points on two consecutive days: before and after (60 minute after the start of the meal) breakfast, lunch and main evening meal, before bedtime, and before breakfast on the next day. Mean of the 8-point profile was derived as the mean of all corresponding mean SMPG recorded at 8 different time points. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Fluctuation in the 8-point SMPG Profile
Fluctuation in the 8-point SMPG profile was evaluated after 26 weeks of randomisation. Fluctuation in 8-point SMPG profile was the average absolute difference from the mean of the SMPG profile. The results are based on the last in-trial value.
Time frame: Week 26
Change in FPG
Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in 1,5-anhydroglucitol
Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Percentage of Subjects Reaching HbA1c Target (HbA1c Less Than 7.5 %) According to ISPAD Guidelines
Percentage of participants (yes/no) reaching HbA1c less than 7.5 % according to International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.
Time frame: Week 26
Percentage of Subjects Reaching HbA1c Target (HbA1c Less Than 7.5 %) According to ISPAD Guidelines, Without Severe Hypoglycaemia
Percentage of participants (yes/no) reaching HbA1c less than 7.5 % according to ISPAD guidelines, without severe hypoglycaemia was evaluated after 26 weeks of randomisation. Severe hypoglycaemia according to ISPAD guidelines: hypoglycaemic episode associated with severe neuroglycopenia, usually resulting in coma or seizure and requiring parenteral therapy (glucagon or intravenous glucose). The results are based on the last in-trial value.
Time frame: Week 26
Insulin Dose (Units/Day): Total Basal
Total basal insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period: the observation period from date of first dose of randomised NovoRapid®/NovoLog® / faster aspart and no later than 7 days after the day of last dose of NovoRapid®/NovoLog® / faster aspart. The on-treatment observation period includes data collected up to and including 7 days after treatment discontinuation. Number of participants analysed = number of participants contributed to the analysis. Analysis population description: Safety analysis set (SAS) included all participants receiving at least one dose of the investigational product (faster aspart) or its comparator (NovoRapid®/NovoLog®).
Time frame: Week 26
Insulin Dose (Units/Day): Total Bolus
Total bolus insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 26
Insulin Dose (Units/Day): Individual Meal Insulin Dose
Individual meal (breakfast, lunch and main evening meal) insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.
Time frame: Week 26
Insulin Dose (Units/kg/Day): Total Basal
Total basal insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 26
Insulin Dose (Units/kg/Day): Total Bolus
Total bolus insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 26
Insulin Dose (Units/kg/Day): Individual Meal Insulin Dose
Individual meal (breakfast, lunch and main evening meal) insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 26
Change of Time Spent in Low Interstitial Glucose (IG) (IG <=3.9 mmol/L [70 mg/dL])
Change from baseline (week 0) in the time spent in low IG (\<=3.9 mmol/L \[70 mg/dL\]) based on continuous glucose monitoring (CGM) was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Incidence of Episodes With IG <=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG >10.0, 12.0 mmol/L (180, 216 mg/dL)
Incidence of episodes (number of episodes per 24 hours) with IG \<=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG \>10.0, 12.0 mmol/L (180, 216 mg/dL) based on CGM was calculated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
Time frame: Week 26
Percentage of Time Spent With IG <=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG >10.0, 12.0 mmol/L (180, 216 mg/dL)
Percentage of time spent with IG \<=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG \>10.0, 12.0 mmol/L (180, 216 mg/dL) based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
Time frame: Week 26
Percentage of Time Spent Within IG Target 4.0-10.0 mmol/L (71-180 mg/dL) Both Included
Percentage of time spent within IG target 4.0-10.0 mmol/L (71-180 mg/dL), both included based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
Time frame: Week 26
Change in Mean IG Increment (0-1 Hours and 0-2 Hours After Start of the Meal)
Change from baseline (week 0) in mean IG increment (0-1 hours and 0-2 hours after start of the meal) based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in Mean IG Peak After Start of Meal
Change from baseline (week 0) in mean IG peak after start of meal based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in Mean Time to the IG Peak After Meal
Change from baseline (week 0) in mean time to the IG peak after meal based on CGM was evaluated after 26 weeks of randomisation. A subgroup of subjects wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in 30-minute PPG
Change from baseline (week 0) in 30-minute PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 30-minute after the meal intake at the visit. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in 30-minute PPG Increment
Change from baseline (week 0) in 30-minute PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 30-minute (after the meal) at the visit. PPG increment was derived as 30-minute PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in 1-hour PPG
Change from baseline (week 0) in 1-hour PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 1-hour after the meal intake at the visit. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in 1-hour PPG Increment
Change from baseline (week 0) in 1-hour PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 1-hour (after the meal) at the visit. PPG increment was derived as 1-hour PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in 2-hour PPG
Change from baseline (week 0) in 2-hour PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 2-hour after the meal intake at the visit. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in 2-hour PPG Increment
Change from baseline (week 0) in 2-hour PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 2-hour (after the meal) at the visit. PPG increment was derived as 2-hour PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in AUCIG,0-15min
Change in area under the IG curve 0-15 minutes post meal (AUCIG,0-15min) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. Interstitial glucose (IG) was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in AUCIG,0-30min
Change in area under the IG curve 0-30 minutes post meal (AUCIG,0-30min) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in AUCIG,0-1h
Change in area under the IG curve 0-1 hour post meal (AUCIG,0-1h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in AUCIG,0-2h
Change in area under the IG curve 0-2 hours post meal (AUCIG,0-2h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in AUCIG,0-4h
Change in area under the IG curve 0-4 hours post meal (AUCIG,0-4h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in Time to the IG Peak After Start of Meal
Change in time to the IG peak after start of meal during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Change in IG Peak After Start of Meal
Change in IG peak after start of meal during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.
Time frame: Week 0, Week 26
Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA)/ISPAD Classification: Total
Treatment emergent: if the onset of the episode occurred on or after the first day of treatment with investigational medicinal product (IMP) after randomisation, and no later than 1 day after the last day on IMP. Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic: episode during which typical symptoms of hypoglycaemia are accompanied by a PG level ≤3.9 mmol/L. 3) Asymptomatic: episode not accompanied by typical symptoms of hypoglycaemia, but with a PG level ≤3.9 mmol/L. 4) Probable symptomatic: an episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG level ≤3.9 mmol/L. 5) Pseudo-hypoglycaemia: episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a PG level \>3.9mmol/L, but approaching that level. The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Hypoglycaemic Episodes According to ADA/ISPAD Classification: Daytime
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. Daytime period: The period between 07:01 and 22:59 (both included). The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Hypoglycaemic Episodes According to ADA/ISPAD Classification: Nocturnal (23:00-7:00, Both Included)
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. Nocturnal period: The period between 23:00 and 07:00 (both included). The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Total
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) Symptomatic blood glucose (BG) confirmed: episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3) Asymptomatic BG confirmed: episode that is BG confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. 4) Severe or BG confirmed symptomatic: an episode that is severe according to the ISPAD classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. 5) BG confirmed: an episode that is BG confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. 6) Severe or BG confirmed: an episode that is severe according to the ISPAD Classification or BG confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Daytime
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. Daytime period: The period between 07:01 and 22:59 (both included). The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification: Nocturnal (23:00-7:00, Both Included)
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. Nocturnal period: The period between 23:00 and 07:00 (both included). The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Meal Related (From Start of Meal Until 1 Hour After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Meal Related (From Start of Meal Until 2 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Meal Related (From Start of Meal Until 4 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Meal Related (From 2-4 Hours After Start of Meal) Hypoglycaemic Episodes According to ADA/ISPAD Classification
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Meal Related (From Start of Meal Until 1 Hour After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Meal Related (From Start of Meal Until 2 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Meal Related (From Start of Meal Until 4 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Meal Related (From 2-4 Hours After Start of Meal) Hypoglycaemic Episodes According to Novo Nordisk/ISPAD Classification
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Adverse Events (AEs)
Treatment emergent was defined as an event that has onset up to 7 days after last day of IMP (faster aspart or NovoRapid®/NovoLog®) and excluding the events occurring in the run-in period. The results are based on the on-treatment period.
Time frame: Week 0-26
Number of Treatment Emergent Injection Site Reactions
Treatment emergent was defined as an event that has onset up to 7 days after last day of IMP and excluding the events occurring in the run-in period. The results are based on the on-treatment period.
Time frame: Week 0-26
Change in Physical Examination
The following physical examinations were done: 1) Cardiovascular system. 2) Central and peripheral nervous system. 3) Gastrointestinal system including the mouth. 4) General appearance. 5) Head, ears, eyes, nose, throat and neck. 6) Musculoskeletal system. 7) Respiratory system. 8) Skin. Presented results are number of participants with the following outcomes: normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS). Presented results are baseline (week 0) and last on-treatment values. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Vital Sign: Blood Pressure
Change from baseline (week 0) in blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.
Time frame: Week 0, Week 26
Change in Vital Sign: Pulse
Change from baseline (week 0) in pulse was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.
Time frame: Week 0, Week 26
Change in Body Weight
Change from baseline (week 0) in body weight was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Height
Change from baseline (week 0) in height was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Body Mass Index
Change from baseline (week 0) in body mass index (BMI) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in SD Score of Body Weight
Change from baseline (week 0) in standard deviation (SD) score of body weight was evaluated after 26 weeks of randomisation. SD-scores are defined to be able to normalise the body weight in the various age groups. To estimate the growth of children, standardised weight is calculated for each year of age and for each sex. Thus, a child with a weight equal to the mean value for its age and sex has an SD score of 0, while a child with a weight 2 SDs above the mean value for its age and sex has an SD score of +2. The SD scores are derived from the age and sex of the subjects and the body weight together with growth curves defined for a reference population. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in SD Score of Body Mass Index
Change from baseline (week 0) in SD score of BMI was evaluated after 26 weeks of randomisation. SD scores for BMI were determined in a similar way as SD scores for weight by use of a suitable reference population based on age and sex. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Haematology: Haemoglobin
Change from baseline (week 0) in haemoglobin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Haematology: Haematocrit
Change from baseline (week 0) in haematocrit was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Haematology: Erythrocytes
Change from baseline (week 0) in erythrocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Haematology: Thrombocytes
Change from baseline (week 0) in thrombocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Haematology: Leukocytes
Change from baseline (week 0) in leukocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Biochemistry: Creatinine
Change from baseline (week 0) in creatinine was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Biochemistry: Alanine Aminotransferase (ALT)
Change from baseline (week 0) in ALT was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Biochemistry: Aspartate Aminotransferase (AST)
Change from baseline (week 0) in AST was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Biochemistry: Alkaline Phosphatase (AP)
Change from baseline (week 0) in AP was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Biochemistry: Sodium
Change from baseline (week 0) in sodium was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Biochemistry: Potassium
Change from baseline (week 0) in potassium was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Biochemistry: Albumin
Change from baseline (week 0) in albumin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Biochemistry: Total Bilirubin
Change from baseline (week 0) in total bilirubin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
Time frame: Week 0, Week 26
Change in Lipid Profile: Total Cholesterol
Change from baseline (week 0) in total cholesterol after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.
Time frame: Week 0, Week 26
Change in Lipid Profile: High Density Lipoproteins (HDL)
Change from baseline (week 0) in HDL after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.
Time frame: Week 0, Week 26
Change in Lipid Profile: Low Density Lipoproteins (LDL)
Change from baseline (week 0) in LDL after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.
Time frame: Week 0, Week 26
Change in Anti-insulin Aspart Antibody Development: Specific
Change from baseline (week 0) in 'antibodies specific for insulin aspart' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.
Time frame: Week 0, Week 26
Change in Anti-insulin Aspart Antibody Development: Cross-reacting With Human Insulin
Change from baseline (week 0) in 'antibodies for insulin aspart, those cross-reacting with human insulin' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.
Time frame: Week 0, Week 26
Change in Anti-insulin Aspart Antibody Development: Total
Change from baseline (week 0) in 'total anti-insulin aspart antibodies (specific for insulin aspart and those cross-reacting with human insulin)' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.
Time frame: Week 0, Week 26
The trial was conducted at 150 sites in 17 countries(number of sites with screened/randomised subjects)-Bulgaria: 4/4; Czech Republic: 6/6; Estonia: 2/2; Finland: 3/3; Germany: 6/6; India: 7/7; Israel: 6/6; Italy: 5/5; Japan: 34/34; Latvia: 1/1; Lithuania: 1/1; Poland: 4/4; Russia: 11/11; Serbia: 4/4; Turkey: 7/7; Ukraine: 9/9; United States: 40/39
| Milestone | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Started | 260 | 259 | 258 |
| Completed | 256 | 251 | 253 |
| Not completed | 4 | 8 | 5 |
| Withdrew: Withdrawal by subject | 0 | 1 | 4 |
| Withdrew: Withdrawal by parent/guardian | 4 | 4 | 1 |
| Withdrew: Unclassified | 0 | 3 | 0 |
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In-trial period: the observation period from date of randomisation until last trial-related participant-site contact and included data collected after a subject discontinued trial product.
| Percentage of HbA1c | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 7.57 ± 0.80 | 7.58 ± 0.84 | 7.53 ± 0.83 |
| Change from baseline | 0.06 ± 0.80 | 0.33 ± 0.83 | 0.23 ± 0.82 |
Change from baseline (week 0) in mean post prandial glucose (PPG) over all three meals was evaluated after 26 weeks of randomisation. PPG for each meal (breakfast, lunch and main evening meal) was recorded by the participant as part of the 8-point self-measured plasma glucose (SMPG) profile. Mean PPG over all three meals was derived as the mean of all corresponding mean meal. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 10.19 ± 2.64 | 10.12 ± 2.79 | 10.03 ± 2.52 |
| Change from baseline | -0.94 ± 2.55 | 0.36 ± 3.17 | -0.21 ± 2.79 |
Change from baseline (week 0) in mean PPG increment over all three meals was evaluated after 26 weeks of randomisation. Postprandial glucose (PPG) increment for each meal (breakfast, lunch and main evening meal) was derived from the 8-point profile as the difference between PPG (1 hour after the meal) values and the plasma glucose (PG) value before meal. The mean of the derived increments was then calculated separately for each meal. Mean PPG increment over all three meals was derived as the mean of all corresponding mean meal increments. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 1.20 ± 2.70 | 1.01 ± 2.48 | 0.97 ± 2.55 |
| Change from baseline | -0.92 ± 2.92 | 0.56 ± 2.88 | 0.14 ± 2.75 |
Change from baseline (week 0) in individual meal (breakfast, lunch and main evening meal) PPG was evaluated after 26 weeks of randomisation. PPG for each meal was recorded by the participant as part of the 8-point SMPG profile. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Breakfast: Baseline | 10.51 ± 3.59 | 10.51 ± 3.77 | 10.49 ± 3.59 |
| Breakfast: Change from baseline | -1.11 ± 3.91 | 0.16 ± 3.95 | 0.04 ± 3.89 |
| Lunch: Baseline | 9.69 ± 3.32 | 9.99 ± 3.82 | 9.62 ± 3.30 |
| Lunch: Change from baseline | -0.80 ± 3.74 | 0.18 ± 4.40 | -0.24 ± 4.22 |
| Main evening meal: Baseline | 10.24 ± 3.64 | 9.90 ± 3.59 | 9.87 ± 3.46 |
| Main evening meal: Change from baseline | -0.74 ± 3.96 | 0.61 ± 4.40 | -0.05 ± 4.14 |
Change from baseline (week 0) in individual meal (breakfast, lunch and main evening meal) PPG increment was evaluated after 26 weeks of randomisation. PPG increment for each meal was derived from the 8-point profile as the difference between PPG values (1 hour after the meal) and the PG value before meal. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Breakfast: Baseline | 1.90 ± 3.64 | 2.10 ± 3.59 | 2.12 ± 4.08 |
| Breakfast: Change from baseline | -0.82 ± 4.44 | 0.46 ± 4.21 | 0.10 ± 4.66 |
| Lunch: Baseline | 1.02 ± 3.82 | 1.12 ± 3.79 | 0.74 ± 3.88 |
| Lunch: Change from baseline | -0.58 ± 4.92 | 0.12 ± 4.41 | -0.11 ± 4.54 |
| Main evening meal: Baseline | 0.53 ± 4.28 | -0.26 ± 3.53 | -0.06 ± 3.78 |
| Main evening meal: Change from baseline | -0.92 ± 5.07 | 1.03 ± 4.68 | 0.45 ± 4.31 |
Change from baseline (week 0) in mean of the 8-point SMPG profile was evaluated after 26 weeks of randomisation. SMPG values were recorded at 8 time-points on two consecutive days: before and after (60 minute after the start of the meal) breakfast, lunch and main evening meal, before bedtime, and before breakfast on the next day. Mean of the 8-point profile was derived as the mean of all corresponding mean SMPG recorded at 8 different time points. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 9.41 ± 1.98 | 9.47 ± 1.89 | 9.39 ± 1.97 |
| Change from baseline | -0.27 ± 2.04 | 0.17 ± 2.12 | -0.05 ± 2.29 |
Fluctuation in the 8-point SMPG profile was evaluated after 26 weeks of randomisation. Fluctuation in 8-point SMPG profile was the average absolute difference from the mean of the SMPG profile. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Fluctuation in the 8-point SMPG Profile | 1.88 ± 44.49 | 1.94 ± 42.51 | 1.83 ± 45.98 |
Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 7.58 ± 3.56 | 8.03 ± 3.35 | 7.79 ± 3.48 |
| Change from baseline | 0.41 ± 5.04 | -0.08 ± 4.49 | -0.13 ± 4.16 |
Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.
| ug/mL | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 4.95 ± 3.62 | 5.07 ± 3.97 | 5.13 ± 3.76 |
| Change from baseline | -0.06 ± 3.13 | -0.85 ± 2.80 | -0.63 ± 2.42 |
Percentage of participants (yes/no) reaching HbA1c less than 7.5 % according to International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines was evaluated after 26 weeks of randomisation. The results are based on the last in-trial value.
| Percentage of participants | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Yes | 42.3 | 31.7 | 39.5 |
| No | 57.7 | 68.3 | 60.5 |
Percentage of participants (yes/no) reaching HbA1c less than 7.5 % according to ISPAD guidelines, without severe hypoglycaemia was evaluated after 26 weeks of randomisation. Severe hypoglycaemia according to ISPAD guidelines: hypoglycaemic episode associated with severe neuroglycopenia, usually resulting in coma or seizure and requiring parenteral therapy (glucagon or intravenous glucose). The results are based on the last in-trial value.
| Percentage of participants | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Yes | 41.9 | 30.9 | 38.4 |
| No | 58.1 | 69.1 | 61.6 |
Total basal insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period: the observation period from date of first dose of randomised NovoRapid®/NovoLog® / faster aspart and no later than 7 days after the day of last dose of NovoRapid®/NovoLog® / faster aspart. The on-treatment observation period includes data collected up to and including 7 days after treatment discontinuation. Number of participants analysed = number of participants contributed to the analysis. Analysis population description: Safety analysis set (SAS) included all participants receiving at least one dose of the investigational product (faster aspart) or its comparator (NovoRapid®/NovoLog®).
| Units (U) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Insulin Dose (Units/Day): Total Basal | 21.6 ± 12.9 | 21.5 ± 14.5 | 20.7 ± 12.8 |
Total bolus insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| Units (U) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Insulin Dose (Units/Day): Total Bolus | 23.3 ± 14.5 | 23.5 ± 15.1 | 22.5 ± 13.0 |
Individual meal (breakfast, lunch and main evening meal) insulin dose (Units/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.
| Units (U) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Breakfast | 7.3 ± 5.1 | 7.1 ± 4.9 | 6.8 ± 4.4 |
| Lunch | 8.1 ± 5.1 | 8.4 ± 6.2 | 7.9 ± 5.2 |
| Main evening meal | 8.1 ± 6.0 | 8.0 ± 5.4 | 7.7 ± 5.1 |
Total basal insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| Units (U)/kg | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Insulin Dose (Units/kg/Day): Total Basal | 0.433 ± 0.228 | 0.425 ± 0.196 | 0.409 ± 0.176 |
Total bolus insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| Units (U)/kg | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Insulin Dose (Units/kg/Day): Total Bolus | 0.483 ± 0.256 | 0.491 ± 0.241 | 0.468 ± 0.224 |
Individual meal (breakfast, lunch and main evening meal) insulin dose (Units/kg/day) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| Units (U)/kg | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Breakfast | 0.151 ± 0.091 | 0.150 ± 0.079 | 0.144 ± 0.081 |
| Lunch | 0.170 ± 0.103 | 0.174 ± 0.104 | 0.166 ± 0.095 |
| Main evening meal | 0.164 ± 0.099 | 0.165 ± 0.092 | 0.158 ± 0.086 |
Change from baseline (week 0) in the time spent in low IG (\<=3.9 mmol/L \[70 mg/dL\]) based on continuous glucose monitoring (CGM) was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
| Minutes/day | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 107.94 ± 77.34 | 100.70 ± 77.28 | 81.52 ± 71.90 |
| Change from baseline | -24.11 ± 71.74 | -13.06 ± 82.55 | 6.92 ± 74.64 |
Incidence of episodes (number of episodes per 24 hours) with IG \<=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG \>10.0, 12.0 mmol/L (180, 216 mg/dL) based on CGM was calculated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
| Episodes per 24 hours | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Episodes with IG <=2.5 mmol/L | 0.55 | 0.68 | 0.57 |
| Episodes with IG <=3.0 mmol/L | 1.01 | 1.10 | 1.03 |
| Episodes with IG <=3.9 mmol/L | 2.29 | 2.30 | 2.24 |
| Episodes with IG >10 mmol/L | 11.52 | 11.61 | 11.65 |
| Episodes with IG >12 mmol/L | 7.64 | 7.77 | 8.05 |
Percentage of time spent with IG \<=2.5, 3.0, 3.9 mmol/L (45, 54, 70 mg/dL) and IG \>10.0, 12.0 mmol/L (180, 216 mg/dL) based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
| Percentage of time | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Time spent with IG <=2.5 mmol/L | 1.09 ± 1.50 | 1.80 ± 3.21 | 1.34 ± 1.90 |
| Time spent with IG <=3.0 mmol/L | 2.19 ± 2.35 | 2.90 ± 4.06 | 2.48 ± 2.92 |
| Time spent with IG <=3.9 mmol/L | 5.97 ± 4.59 | 6.25 ± 5.68 | 5.97 ± 5.38 |
| Time spent with IG >10 mmol/L | 40.40 ± 14.80 | 40.60 ± 14.38 | 42.47 ± 17.51 |
| Time spent with IG >12 mmol/L | 26.09 ± 12.82 | 25.67 ± 13.60 | 28.62 ± 16.83 |
Percentage of time spent within IG target 4.0-10.0 mmol/L (71-180 mg/dL), both included based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
| Percentage of time | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Percentage of Time Spent Within IG Target 4.0-10.0 mmol/L (71-180 mg/dL) Both Included | 53.00 ± 12.15 | 52.56 ± 14.08 | 51.03 ± 16.25 |
Change from baseline (week 0) in mean IG increment (0-1 hours and 0-2 hours after start of the meal) based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| 0-1 hour: Baseline | 0.56 ± 0.58 | 0.73 ± 0.54 | 0.61 ± 0.49 |
| 0-1 hour: Change from baseline | -0.19 ± 0.55 | 0.26 ± 0.83 | 0.07 ± 0.50 |
| 0-2 hour: Baseline | 0.76 ± 0.75 | 1.10 ± 1.03 | 0.86 ± 0.69 |
| 0-2 hour: Change from baseline | -0.35 ± 0.87 | 0.55 ± 1.14 | 0.09 ± 0.59 |
Change from baseline (week 0) in mean IG peak after start of meal based on CGM was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 12.90 ± 1.88 | 12.92 ± 1.97 | 12.90 ± 2.25 |
| Change from baseline | -0.28 ± 1.91 | 0.80 ± 1.84 | 0.38 ± 2.00 |
Change from baseline (week 0) in mean time to the IG peak after meal based on CGM was evaluated after 26 weeks of randomisation. A subgroup of subjects wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.
| Minutes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 103.16 ± 16.87 | 106.21 ± 20.68 | 102.20 ± 17.09 |
| Change from baseline | 4.70 ± 25.85 | -8.56 ± 22.62 | 2.29 ± 19.80 |
Change from baseline (week 0) in 30-minute PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 30-minute after the meal intake at the visit. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 11.28 ± 3.26 | 10.96 ± 3.78 | 11.71 ± 3.13 |
| Change from baseline | -0.21 ± 3.49 | 1.84 ± 3.41 | -0.45 ± 3.42 |
Change from baseline (week 0) in 30-minute PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 30-minute (after the meal) at the visit. PPG increment was derived as 30-minute PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 3.44 ± 2.16 | 3.48 ± 2.50 | 4.02 ± 2.18 |
| Change from baseline | 0.36 ± 2.92 | 1.92 ± 2.79 | -0.34 ± 2.18 |
Change from baseline (week 0) in 1-hour PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 1-hour after the meal intake at the visit. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 12.77 ± 3.92 | 12.56 ± 5.08 | 13.06 ± 3.86 |
| Change from baseline | -0.15 ± 4.39 | 2.54 ± 4.43 | -0.63 ± 4.73 |
Change from baseline (week 0) in 1-hour PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 1-hour (after the meal) at the visit. PPG increment was derived as 1-hour PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 4.93 ± 3.34 | 5.08 ± 4.21 | 5.36 ± 2.77 |
| Change from baseline | 0.42 ± 4.93 | 2.63 ± 4.03 | -0.52 ± 3.17 |
Change from baseline (week 0) in 2-hour PPG based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the PPG at 2-hour after the meal intake at the visit. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 12.50 ± 4.63 | 12.54 ± 5.74 | 12.37 ± 4.74 |
| Change from baseline | 0.69 ± 5.88 | 1.80 ± 5.08 | -0.75 ± 5.64 |
Change from baseline (week 0) in 2-hour PPG increment based on meal test was evaluated after 26 weeks of randomisation. In connection to wearing the CGM for 11 to 13 days up to week 0 and up to week 26, the subgroup of participants had a standardised liquid meal test at the 2 visits, monitoring the pre-prandial glucose (before the meal) the PPG at 2-hour (after the meal) at the visit. PPG increment was derived as 2-hour PPG measurement minus the pre-prandial PG. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 4.66 ± 4.22 | 5.06 ± 5.04 | 4.67 ± 3.83 |
| Change from baseline | 1.26 ± 6.81 | 1.62 ± 5.03 | -0.64 ± 4.43 |
Change in area under the IG curve 0-15 minutes post meal (AUCIG,0-15min) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. Interstitial glucose (IG) was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 8.01 ± 2.72 | 7.49 ± 2.07 | 7.66 ± 1.96 |
| Change from baseline | -1.27 ± 3.68 | 0.08 ± 2.48 | -0.53 ± 2.85 |
Change in area under the IG curve 0-30 minutes post meal (AUCIG,0-30min) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 8.28 ± 2.75 | 7.80 ± 2.13 | 8.13 ± 1.87 |
| Change from baseline | -1.15 ± 3.62 | 0.22 ± 2.52 | -0.47 ± 2.81 |
Change in area under the IG curve 0-1 hour post meal (AUCIG,0-1h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 9.63 ± 2.90 | 9.43 ± 2.71 | 10.02 ± 2.19 |
| Change from baseline | -0.87 ± 3.71 | 0.54 ± 3.00 | -0.65 ± 2.91 |
Change in area under the IG curve 0-2 hours post meal (AUCIG,0-2h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 11.40 ± 3.20 | 11.48 ± 3.43 | 11.76 ± 2.80 |
| Change from baseline | -0.84 ± 3.93 | 0.75 ± 3.74 | -0.86 ± 3.61 |
Change in area under the IG curve 0-4 hours post meal (AUCIG,0-4h) during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. IG was measured every 5 minutes. The endpoint was calculated as the area under the IG curve using the trapezoidal method and weighted by duration. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 11.21 ± 3.25 | 11.19 ± 3.47 | 11.46 ± 3.21 |
| Change from baseline | -0.38 ± 3.96 | 0.62 ± 3.97 | -1.30 ± 4.13 |
Change in time to the IG peak after start of meal during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.
| Minute | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 102.85 ± 48.93 | 94.26 ± 38.22 | 93.80 ± 39.19 |
| Change from baseline | 5.29 ± 55.42 | -0.04 ± 42.05 | -8.76 ± 52.17 |
Change in IG peak after start of meal during meal test and based on CGM measurements was evaluated after 26 weeks of randomisation. A subgroup of participants wore a CGM for between 11 and 13 days up to week 0 (randomisation) and up to week 26 to monitor their IG on a continuous basis. Presented values are mean of all the meals (breakfast, lunch and evening meal). The results are based on the last in-trial value.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 14.87 ± 3.55 | 15.15 ± 4.52 | 15.11 ± 3.62 |
| Change from baseline | -0.55 ± 3.77 | 1.11 ± 4.88 | -1.36 ± 4.36 |
Treatment emergent: if the onset of the episode occurred on or after the first day of treatment with investigational medicinal product (IMP) after randomisation, and no later than 1 day after the last day on IMP. Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic: episode during which typical symptoms of hypoglycaemia are accompanied by a PG level ≤3.9 mmol/L. 3) Asymptomatic: episode not accompanied by typical symptoms of hypoglycaemia, but with a PG level ≤3.9 mmol/L. 4) Probable symptomatic: an episode during which symptoms of hypoglycaemia are not accompanied by a PG determination but that was presumably caused by a PG level ≤3.9 mmol/L. 5) Pseudo-hypoglycaemia: episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a PG level \>3.9mmol/L, but approaching that level. The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 3 | 8 | 4 |
| Documented symptomatic | 5391 | 5712 | 5170 |
| Asymptomatic | 4255 | 3781 | 3656 |
| Probable symptomatic | 12 | 10 | 24 |
| Pseudo-hypoglycaemia | 35 | 37 | 47 |
| Unclassifiable | 5 | 2 | 1 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. Daytime period: The period between 07:01 and 22:59 (both included). The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 3 | 5 | 3 |
| Documented symptomatic | 4895 | 5077 | 4779 |
| Asymptomatic | 3584 | 3163 | 3101 |
| Probable symptomatic | 10 | 10 | 22 |
| Pseudo-hypoglycaemia | 32 | 31 | 42 |
| Unclassifiable | 5 | 2 | 1 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. Nocturnal period: The period between 23:00 and 07:00 (both included). The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 0 | 3 | 1 |
| Documented symptomatic | 496 | 635 | 391 |
| Asymptomatic | 671 | 618 | 555 |
| Probable symptomatic | 2 | 0 | 2 |
| Pseudo-hypoglycaemia | 3 | 6 | 5 |
| Unclassifiable | 0 | 0 | 0 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) Symptomatic blood glucose (BG) confirmed: episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3) Asymptomatic BG confirmed: episode that is BG confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. 4) Severe or BG confirmed symptomatic: an episode that is severe according to the ISPAD classification or BG confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. 5) BG confirmed: an episode that is BG confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. 6) Severe or BG confirmed: an episode that is severe according to the ISPAD Classification or BG confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 3 | 8 | 4 |
| BG confirmed | 3580 | 3586 | 3272 |
| Severe or BG confirmed symptomatic | 2242 | 2427 | 2194 |
| Severe or BG confirmed | 3583 | 3594 | 3276 |
| Unclassifiable | 6118 | 5956 | 5626 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. Daytime period: The period between 07:01 and 22:59 (both included). The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 3 | 5 | 3 |
| BG confirmed | 3184 | 3112 | 2960 |
| Severe or BG confirmed symptomatic | 2062 | 2167 | 2035 |
| Severe or BG confirmed | 3187 | 3117 | 2963 |
| Unclassifiable | 5342 | 5171 | 4985 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. Nocturnal period: The period between 23:00 and 07:00 (both included). The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 0 | 3 | 1 |
| BG confirmed | 396 | 474 | 312 |
| Severe or BG confirmed symptomatic | 180 | 260 | 159 |
| Severe or BG confirmed | 396 | 477 | 313 |
| Unclassifiable | 776 | 785 | 641 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 0 | 0 | 0 |
| Documented symptomatic | 178 | 113 | 157 |
| Asymptomatic | 77 | 51 | 55 |
| Probable symptomatic | 0 | 0 | 1 |
| Pseudo-hypoglycaemia | 1 | 2 | 1 |
| Unclassifiable | 0 | 0 | 0 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 2 | 1 | 1 |
| Documented symptomatic | 1125 | 882 | 1016 |
| Asymptomatic | 421 | 268 | 303 |
| Probable symptomatic | 1 | 1 | 7 |
| Pseudo-hypoglycaemia | 6 | 6 | 4 |
| Unclassifiable | 0 | 0 | 0 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 3 | 1 | 2 |
| Documented symptomatic | 3041 | 3064 | 2812 |
| Asymptomatic | 1340 | 1194 | 1168 |
| Probable symptomatic | 4 | 8 | 16 |
| Pseudo-hypoglycaemia | 15 | 18 | 17 |
| Unclassifiable | 2 | 0 | 0 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to ADA classification: 2) Documented symptomatic. 3) Asymptomatic. 4) Probable symptomatic. 5) Pseudo-hypoglycaemia. The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 1 | 0 | 1 |
| Documented symptomatic | 1916 | 2182 | 1796 |
| Asymptomatic | 919 | 926 | 865 |
| Probable symptomatic | 3 | 7 | 9 |
| Pseudo-hypoglycaemia | 9 | 12 | 13 |
| Unclassifiable | 2 | 0 | 0 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 0 | 0 | 0 |
| BG confirmed | 119 | 66 | 105 |
| Severe or BG confirmed symptomatic | 94 | 49 | 85 |
| Severe or BG confirmed | 119 | 66 | 105 |
| Unclassifiable | 137 | 100 | 109 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 2 | 1 | 1 |
| BG confirmed | 715 | 504 | 600 |
| Severe or BG confirmed symptomatic | 572 | 414 | 495 |
| Severe or BG confirmed | 717 | 505 | 601 |
| Unclassifiable | 838 | 653 | 730 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 3 | 1 | 2 |
| BG confirmed | 1774 | 1781 | 1666 |
| Severe or BG confirmed symptomatic | 1365 | 1375 | 1277 |
| Severe or BG confirmed | 1777 | 1782 | 1668 |
| Unclassifiable | 2628 | 2503 | 2347 |
Classification of hypoglycaemia: 1) Severe (according to ISPAD classification). Following are according to Novo Nordisk classification: 2) BG confirmed. 3) Severe or BG confirmed symptomatic. 4) Severe or BG confirmed. 5) Asymptomatic BG confirmed. The results are based on the on-treatment period.
| Episodes | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Severe | 1 | 0 | 1 |
| BG confirmed | 1059 | 1277 | 1066 |
| Severe or BG confirmed symptomatic | 793 | 961 | 782 |
| Severe or BG confirmed | 1060 | 1277 | 1067 |
| Unclassifiable | 1790 | 1850 | 1617 |
Treatment emergent was defined as an event that has onset up to 7 days after last day of IMP (faster aspart or NovoRapid®/NovoLog®) and excluding the events occurring in the run-in period. The results are based on the on-treatment period.
| Events | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Number of Treatment Emergent Adverse Events (AEs) | 576 | 678 | 593 |
Treatment emergent was defined as an event that has onset up to 7 days after last day of IMP and excluding the events occurring in the run-in period. The results are based on the on-treatment period.
| Events | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Number of Treatment Emergent Injection Site Reactions | 11 | 31 | 17 |
The following physical examinations were done: 1) Cardiovascular system. 2) Central and peripheral nervous system. 3) Gastrointestinal system including the mouth. 4) General appearance. 5) Head, ears, eyes, nose, throat and neck. 6) Musculoskeletal system. 7) Respiratory system. 8) Skin. Presented results are number of participants with the following outcomes: normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS). Presented results are baseline (week 0) and last on-treatment values. Number of participants analysed = number of participants contributed to the analysis.
| Participants | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| 1) Baseline: Normal | 260 | 254 | 258 |
| 1) Baseline: Abnormal, NCS | 1 | 4 | 0 |
| 1) Baseline: Abnormal, CS | 0 | 0 | 0 |
| 1) Last on-treatment: Normal | 257 | 253 | 257 |
| 1) Last on-treatment: Abnormal, NCS | 0 | 5 | 0 |
| 1) Last on-treatment: Abnormal, CS | 0 | 0 | 0 |
| 2) Baseline: Normal | 257 | 253 | 258 |
| 2) Baseline: Abnormal, NCS | 3 | 4 | 0 |
| 2) Baseline: Abnormal, CS | 1 | 1 | 0 |
| 2) Last on-treatment: Normal | 255 | 253 | 257 |
| 2) Last on-treatment: Abnormal, NCS | 2 | 4 | 0 |
| 2) Last on-treatment: Abnormal, CS | 0 | 1 | 0 |
| 3) Baseline: Normal | 258 | 257 | 254 |
| 3) Baseline: Abnormal, NCS | 3 | 1 | 3 |
| 3) Baseline: Abnormal, CS | 0 | 0 | 1 |
| 3) Last on-treatment: Normal | 253 | 257 | 256 |
| 3) Last on-treatment: Abnormal, NCS | 4 | 1 | 0 |
| 3) Last on-treatment: Abnormal, CS | 0 | 0 | 1 |
| 4) Baseline: Normal | 258 | 253 | 254 |
| 4) Baseline: Abnormal, NCS | 2 | 3 | 4 |
| 4) Baseline: Abnormal, CS | 1 | 2 | 0 |
| 4) Last on-treatment: Normal | 257 | 253 | 254 |
| 4) Last on-treatment: Abnormal, NCS | 0 | 4 | 3 |
| 4) Last on-treatment: Abnormal, CS | 0 | 1 | 0 |
| 5) Baseline: Normal | 251 | 238 | 245 |
| 5) Baseline: Abnormal, NCS | 9 | 13 | 11 |
| 5) Baseline: Abnormal, CS | 1 | 7 | 2 |
| 5) Last on-treatment: Normal | 247 | 244 | 242 |
| 5) Last on-treatment: Abnormal, NCS | 7 | 11 | 14 |
| 5) Last on-treatment: Abnormal, CS | 3 | 3 | 1 |
| 6) Baseline: Normal | 259 | 252 | 254 |
| 6) Baseline: Abnormal, NCS | 2 | 4 | 3 |
| 6) Baseline: Abnormal, CS | 0 | 2 | 1 |
| 6) Last on-treatment: Normal | 254 | 253 | 253 |
| 6) Last on-treatment: Abnormal, NCS | 1 | 3 | 3 |
| 6) Last on-treatment: Abnormal, CS | 2 | 2 | 1 |
| 7) Baseline: Normal | 259 | 256 | 256 |
| 7) Baseline: Abnormal, NCS | 1 | 2 | 1 |
| 7) Baseline: Abnormal, CS | 1 | 0 | 1 |
| 7) Last on-treatment: Normal | 257 | 258 | 257 |
| 7) Last on-treatment: Abnormal, NCS | 0 | 0 | 0 |
| 7) Last on-treatment: Abnormal, CS | 0 | 0 | 0 |
| 8) Baseline: Normal | 239 | 237 | 238 |
| 8) Baseline: Abnormal, NCS | 18 | 21 | 16 |
| 8) Baseline: Abnormal, CS | 4 | 0 | 4 |
| 8) Last on-treatment: Normal | 229 | 233 | 235 |
| 8) Last on-treatment: Abnormal, NCS | 19 | 22 | 17 |
| 8) Last on-treatment: Abnormal, CS | 9 | 3 | 5 |
Change from baseline (week 0) in blood pressure (systolic blood pressure (SBP) and diastolic blood pressure (DBP)) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.
| mmHg | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| SBP: Baseline | 106.4 ± 11.8 | 107.0 ± 12.6 | 106.8 ± 11.4 |
| SBP: Change from baseline | 0.8 ± 11.0 | 1.5 ± 10.4 | 1.1 ± 10.1 |
| DBP: Baseline | 65.4 ± 8.3 | 65.7 ± 9.4 | 65.4 ± 7.9 |
| DBP: Change from baseline | 1.2 ± 9.1 | 1.4 ± 9.3 | 1.4 ± 8.3 |
Change from baseline (week 0) in pulse was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value.
| Beats/minute | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 80.6 ± 11.8 | 80.5 ± 11.8 | 79.4 ± 11.8 |
| Change from baseline | -0.6 ± 10.3 | 0.3 ± 10.8 | 0.7 ± 11.0 |
Change from baseline (week 0) in body weight was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| kg | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 46.69 ± 18.15 | 46.48 ± 18.98 | 46.28 ± 17.18 |
| Change from baseline | 2.21 ± 2.57 | 1.90 ± 2.32 | 2.15 ± 2.80 |
Change from baseline (week 0) in height was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| Meter | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 1.50 ± 0.21 | 1.50 ± 0.21 | 1.50 ± 0.19 |
| Change from baseline | 0.02 ± 0.02 | 0.02 ± 0.02 | 0.02 ± 0.02 |
Change from baseline (week 0) in body mass index (BMI) was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| kg/m^2 | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 19.68 ± 3.75 | 19.67 ± 4.02 | 19.64 ± 3.78 |
| Change from baseline | 0.37 ± 0.92 | 0.28 ± 0.92 | 0.34 ± 1.10 |
Change from baseline (week 0) in standard deviation (SD) score of body weight was evaluated after 26 weeks of randomisation. SD-scores are defined to be able to normalise the body weight in the various age groups. To estimate the growth of children, standardised weight is calculated for each year of age and for each sex. Thus, a child with a weight equal to the mean value for its age and sex has an SD score of 0, while a child with a weight 2 SDs above the mean value for its age and sex has an SD score of +2. The SD scores are derived from the age and sex of the subjects and the body weight together with growth curves defined for a reference population. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| Standard deviation score | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 0.349 ± 0.945 | 0.351 ± 0.936 | 0.361 ± 0.875 |
| Change from baseline | 0.034 ± 0.231 | 0.008 ± 0.223 | 0.030 ± 0.250 |
Change from baseline (week 0) in SD score of BMI was evaluated after 26 weeks of randomisation. SD scores for BMI were determined in a similar way as SD scores for weight by use of a suitable reference population based on age and sex. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| Standard deviation score | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 0.296 ± 0.895 | 0.298 ± 0.936 | 0.317 ± 0.898 |
| Change from baseline | 0.016 ± 0.308 | 0.004 ± 0.370 | 0.007 ± 0.338 |
Change from baseline (week 0) in haemoglobin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 8.33 ± 0.72 | 8.47 ± 0.74 | 8.41 ± 0.77 |
| Change from baseline | 0.08 ± 0.51 | 0.09 ± 0.62 | 0.09 ± 0.52 |
Change from baseline (week 0) in haematocrit was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| % of red blood cells | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 40.87 ± 3.39 | 41.51 ± 3.50 | 41.34 ± 3.75 |
| Change from baseline | 0.45 ± 2.86 | 0.40 ± 3.09 | 0.32 ± 2.75 |
Change from baseline (week 0) in erythrocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| 10^12 cells/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 4.81 ± 0.39 | 4.87 ± 0.39 | 4.88 ± 0.40 |
| Change from baseline | 0.02 ± 0.27 | 0.04 ± 0.31 | 0.02 ± 0.26 |
Change from baseline (week 0) in thrombocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| 10^9 cells/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 268.1 ± 64.5 | 270.0 ± 60.2 | 262.5 ± 57.9 |
| Change from baseline | 1.2 ± 47.3 | 1.6 ± 45.4 | 6.0 ± 44.9 |
Change from baseline (week 0) in leukocytes was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| 10^9 cells/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 6.10 ± 1.65 | 6.10 ± 1.63 | 6.11 ± 1.81 |
| Change from baseline | 0.08 ± 1.66 | 0.14 ± 1.74 | 0.10 ± 1.67 |
Change from baseline (week 0) in creatinine was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| umol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 51.8 ± 14.2 | 52.6 ± 13.3 | 52.1 ± 12.3 |
| Change from baseline | 1.1 ± 7.8 | 1.5 ± 6.9 | 1.7 ± 6.8 |
Change from baseline (week 0) in ALT was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| U/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 14.4 ± 6.4 | 14.7 ± 7.4 | 14.8 ± 5.6 |
| Change from baseline | 0.1 ± 6.9 | 1.3 ± 14.9 | 0.5 ± 5.9 |
Change from baseline (week 0) in AST was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| U/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 19.9 ± 6.8 | 20.0 ± 5.6 | 20.5 ± 5.9 |
| Change from baseline | 0.1 ± 6.2 | 1.1 ± 11.7 | -0.4 ± 5.0 |
Change from baseline (week 0) in AP was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| U/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 212.7 ± 135.8 | 209.8 ± 94.9 | 226.2 ± 93.6 |
| Change from baseline | -3.0 ± 119.0 | -1.7 ± 50.8 | -2.8 ± 80.4 |
Change from baseline (week 0) in sodium was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 139.5 ± 2.5 | 139.6 ± 2.4 | 139.7 ± 2.5 |
| Change from baseline | 0.5 ± 2.8 | 0.3 ± 2.7 | 0.04 ± 2.8 |
Change from baseline (week 0) in potassium was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| mmol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 4.48 ± 0.34 | 4.52 ± 0.34 | 4.52 ± 0.40 |
| Change from baseline | 0.02 ± 0.41 | -0.06 ± 0.34 | 0.01 ± 0.50 |
Change from baseline (week 0) in albumin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| g/dL | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 4.47 ± 0.24 | 4.51 ± 0.24 | 4.50 ± 0.25 |
| Change from baseline | 0.01 ± 0.24 | 0.01 ± 0.25 | 0.005 ± 0.24 |
Change from baseline (week 0) in total bilirubin was evaluated after 26 weeks of randomisation. The results are based on the last on-treatment value. Number of participants analysed = number of participants contributed to the analysis.
| umol/L | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 7.9 ± 6.0 | 7.9 ± 5.3 | 8.0 ± 6.2 |
| Change from baseline | 0.2 ± 4.9 | 0.2 ± 3.4 | 0.3 ± 4.1 |
Change from baseline (week 0) in total cholesterol after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.
| Ratio | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change in Lipid Profile: Total Cholesterol | 0.989 ± 13.869 | 1.023 ± 13.742 | 1.016 ± 13.187 |
Change from baseline (week 0) in HDL after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.
| Ratio | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change in Lipid Profile: High Density Lipoproteins (HDL) | 1.004 ± 17.865 | 1.030 ± 20.180 | 1.023 ± 17.852 |
Change from baseline (week 0) in LDL after 26 weeks of randomisation is presented as ratio to baseline values. The results are based on the last on-treatment value.
| Ratio | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Change in Lipid Profile: Low Density Lipoproteins (LDL) | 1.014 ± 19.533 | 1.040 ± 19.685 | 1.041 ± 19.864 |
Change from baseline (week 0) in 'antibodies specific for insulin aspart' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.
| Percentage of B/T | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 1.436 ± 3.159 | 1.459 ± 5.313 | 1.183 ± 2.134 |
| Change from baseline | -0.099 ± 1.015 | -0.213 ± 1.661 | -0.201 ± 1.238 |
Change from baseline (week 0) in 'antibodies for insulin aspart, those cross-reacting with human insulin' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.
| Percentage of B/T | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 18.794 ± 17.189 | 21.576 ± 17.721 | 20.156 ± 17.315 |
| Change from baseline | -3.202 ± 6.989 | -4.845 ± 7.034 | -3.802 ± 7.587 |
Change from baseline (week 0) in 'total anti-insulin aspart antibodies (specific for insulin aspart and those cross-reacting with human insulin)' was evaluated after 26 weeks of randomisation. This endpoint was measured as % bound radioactivity-labelled insulin aspart/Total added radioactivity-labelled insulin aspart (%B/T). The results are based on the last on-treatment value.
| Percentage of B/T | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Baseline | 20.230 ± 17.795 | 23.044 ± 18.070 | 21.344 ± 17.825 |
| Change from baseline | -3.271 ± 7.158 | -5.061 ± 7.193 | -4.004 ± 7.700 |
Collected over Week 0 to week 26 + 7 days. Presented adverse events are treatment emergent.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Faster Aspart (Meal) | 0/261 (0%) | 5/261 (1.9%) | 137/261 (52.5%) |
| Faster Aspart (Post) | 0/258 (0%) | 13/258 (5%) | 149/258 (57.8%) |
| NovoRapid (Meal) | 0/258 (0%) | 9/258 (3.5%) | 136/258 (52.7%) |
| Event | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| GastroenteritisInfections and infestations | 0/261 | 0/258 | 3/258 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/261 | 2/258 | 0/258 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/261 | 2/258 | 2/258 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/261 | 2/258 | 1/258 |
| Hypoglycaemic unconsciousnessNervous system disorders | 0/261 | 2/258 | 0/258 |
| AppendicitisInfections and infestations | 2/261 | 0/258 | 0/258 |
| Abdominal painGastrointestinal disorders | 0/261 | 0/258 | 1/258 |
| Adjustment disorder with mixed disturbance of emotion and conductPsychiatric disorders | 0/261 | 1/258 | 0/258 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/261 | 0/258 | 1/258 |
| Diabetes mellitus managementSurgical and medical procedures | 0/261 | 1/258 | 0/258 |
| Event | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) |
|---|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 60/261 | 53/258 | 48/258 |
| Upper respiratory tract infectionInfections and infestations | 22/261 | 32/258 | 26/258 |
| HeadacheNervous system disorders | 16/261 | 26/258 | 22/258 |
| PyrexiaGeneral disorders | 22/261 | 16/258 | 18/258 |
| VomitingGastrointestinal disorders | 9/261 | 21/258 | 7/258 |
| InfluenzaInfections and infestations | 20/261 | 14/258 | 14/258 |
| GastroenteritisInfections and infestations | 13/261 | 16/258 | 19/258 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/261 | 11/258 | 16/258 |
| RhinitisInfections and infestations | 10/261 | 16/258 | 11/258 |
| Viral infectionInfections and infestations | 7/261 | 9/258 | 14/258 |
| Age, Continuous(Years) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) | Total |
|---|---|---|---|---|
| Mean | 11.72 ± 3.74 | 11.62 ± 3.65 | 11.70 ± 3.44 | 11.68 ± 3.61 |
| Sex: Female, Male(Participants) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) | Total |
|---|---|---|---|---|
| Female | 126 | 122 | 110 | 358 |
| Male | 134 | 137 | 148 | 419 |
| Ethnicity (NIH/OMB)(Participants) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 16 | 17 | 12 | 45 |
| Not Hispanic or Latino | 244 | 242 | 246 | 732 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Faster Aspart (Meal) | Faster Aspart (Post) | NovoRapid (Meal) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 2 |
| Asian | 46 | 37 | 43 | 126 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 4 | 5 | 15 |
| White | 206 | 217 | 209 | 632 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 2 |
Showing the first 100 of 155 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2016 to primary completion in Feb 2018, 21 months.
Results were first posted in Apr 2019, 1 year 1 month after primary completion.
Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 21 months is above that.
Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Aspart